REFERENCES
- Coyle J., Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol. Psych. 2001; 49: 289–299
- Erkinjuntti T. Treatment options: the latest evidence with galantamine (Reminyl®). J. Neurol. Sci. 2002; 203–204: 125–130
- Farlow M. R. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implication for switching to galantamine. Clinic Therap 2001; 23(suppl A)13–24
- Huang F. L., Lasseter K. C., Janssens L., Verhaeghe T., Lau H., Zhao Q. Pharmacokinetic and safety assessments of galantamine and Risperidone after the two drugs are administrated alone and together. J. Clin. Pharmacol. 2002; 42: 1341–1351
- Migliaccio-Walle K., Getsios D., Caro J. J., Ishak K. J., O'Brien J. A., Papadopoulos G. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clinic. Therap. 2003; 25: 1806–1825
- Standridge J. B. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clinic. Therap. 2004; 26: 615–630
- Suh G. H., Yeon Jung H., UK Lee C., Hoon Oh B., Nam Bae J., Jung H. Y., Ju Y. S., Kil Yeon B., Park J., Hong I., Choi S., Ho Lee J. A prospective, double-blind, community controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clinic. Therap. 2004; 26: 1608–1618
- Verhaeghe T., Diels L., Vries de R., De Mevlder M., De Jong J. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of galantamine in human heparinised plasma. J. Chromatogr. B 2003; 789: 337–346
- Zhao Q. Y., Brett M., Van Osselaer N., Huang F., Raoult A., Van Peer A., Verhaeghe T., Hust R. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. J. Clin. Pharmacol. 2002; 42: 1002–1010